LB Pharmaceuticals Inc (LBRX)
$37.22+7.54%Close
SELLCRISIS · day 13
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.1B
- Beta
- 0.42
- P/E (TTM)
- -11.54
- Short % float
- 28.95%
- Days to cover
- 14.5
- SI change
- +7.0%
- 1W
- +0.62%
- 1M
- -19.52%
- vs SPY 1W
- -0.54%
- vs SPY 1M
- -22.52%
Industry peers
FMP comparable companies · ranked by market cap
- DFTXSELLDefinium Therapeutics, Inc.$4.9BBEARQ 26$36.90+7.96%
- ACADSELLAcadia Pharmaceuticals Inc.$3.4BCRISISQ 18$19.78+1.02%
- DNLISELLDenali Therapeutics Inc.$3.1BCRISISQ 8$19.45+4.18%
- RAPPSELLRapport Therapeutics, Inc. Common Stock$1.5BCRISISQ 26$30.65+2.68%
- GHRSSELLGH Research PLC$1.4BCRISISQ 16$21.11+3.23%
- SPTXSELLSeaport Therapeutics, Inc. Common Stock$972MQ -0$18.15+1.34%
- ANROSELLAlto Neuroscience, Inc.$855MCRISISQ 17$24.37+1.41%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on LBRX?
- LOPJLB’s latest quantitative signal on LB Pharmaceuticals Inc Common Stock (LBRX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is LBRX in?
- LB Pharmaceuticals Inc Common Stock (LBRX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does LB Pharmaceuticals Inc Common Stock (LBRX) do?
- This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.